Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plant-Derived Vesicle-like Nanoparticles for Cancer Therapy: From Drug Delivery to Combined Immunotherapy.

Antioxidants (Basel, Switzerland)·2026

Same author

A New Perspective on Regenerative Medicine: Plant-Derived Extracellular Vesicles.

Biomolecules·2025

Same author

Effects of Saffron Supplementation on Glycolipid Metabolism and Blood Pressure in Patients With Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Phytotherapy research : PTR·2025

Same author

The Effects of Okra Consumption on Glycemic Parameters and Lipid Profile in Adults: A Systematic Review and Meta-Analysis.

Food science & nutrition·2024

Same author

Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression.

Canadian respiratory journal·2023

Same author

Using a System Pharmacology Method to Search for the Potential Targets and Pathways of Yinqiaosan against COVID-19.

Journal of healthcare engineering·2022

Search research articles

Related Experiment Video

Updated: May 28, 2026

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Engineered Plant-Derived Extracellular Vesicles: A Novel Strategy for Tumor-Targeted Therapy.

Yuan Zuo¹, Jinying Zhang¹, Xinxin Wang¹

¹Academy of Traditional Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, China.

|May 27, 2026

Summary

Plant-derived extracellular vesicles (PDEVs) show promise for cancer therapy due to their biocompatibility. Engineering strategies are being developed to overcome limitations in targeting and drug delivery for improved cancer treatment.

Keywords:

artificial bionic cancer covalent and noncovalent modifications drug delivery engineered plant-derived exosome-like nanovesicles nanocarriers surface modification

More Related Videos

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Related Experiment Videos

Last Updated: May 28, 2026

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Published on: August 16, 2024

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Area of Science:

Oncology
Nanomedicine
Biotechnology

Background:

Cancer is a leading cause of global mortality, with current therapies like chemotherapy and radiotherapy limited by toxicity to healthy tissues.
Plant-derived extracellular vesicles (PDEVs) are emerging as novel therapeutic vehicles for cancer treatment, offering high biocompatibility and low immunogenicity.
Despite their potential, PDEVs face challenges in clinical translation, including poor targeting specificity, inefficient drug loading, and production scalability.

Purpose of the Study:

To provide a comprehensive overview of plant-derived extracellular vesicles (PDEVs) for cancer therapy.
To focus on engineering strategies aimed at enhancing the active targeting capabilities of PDEVs.
To offer theoretical insights into the future role of engineered PDEVs in cancer treatment.

Main Methods:

Review of existing literature on PDEV isolation, biogenesis, physicochemical properties, and anticancer applications.
Analysis of current engineering strategies for enhancing PDEV targeting specificity, such as surface modification with peptides or antibodies.
Examination of methods to optimize PDEV production and drug-loading efficiency.

Main Results:

PDEVs possess inherent advantages for cancer therapy, including biocompatibility and low immunogenicity.
Engineering approaches, including surface functionalization and process optimization, are crucial for overcoming PDEV limitations.
Enhanced PDEVs demonstrate potential for next-generation targeted cancer therapeutics.

Conclusions:

Engineered PDEVs represent a promising platform for advancing targeted cancer therapy.
Further research and development in PDEV engineering are essential for clinical translation.
PDEVs hold significant potential to improve the efficacy and reduce the toxicity of cancer treatments.